* By analyzing various databases, we identified 79 common drug and disease targets, with important genes like HSP90AA1 and JUN linked to critical signaling pathways involved in inflammation and cellular responses.
* In laboratory tests with a rat model of ARDS, BRE demonstrated protective effects by reducing inflammation, improving histopathological conditions, and showing promising binding interactions with target proteins, highlighting its potential as a therapeutic option for ARDS.